Investor Relations

Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates

Multiple Top-line Phase 2 Clinical Efficacy Readouts from Wholly-owned Pipeline Anticipated in 2019 Etokimab Phase 2a Severe Eosinophilic Asthma Data to be Presented at the 2019 EAACI Congress IND Filing for New Wholly-owned Anti-inflammatory Program Anticipated in Second Half of 2019 SAN DIEGO ,

AnaptysBio to Present at the Bank of America Merrill Lynch Healthcare Conference

SAN DIEGO , May 01, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio , will

AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference

SAN DIEGO , March 04, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria , chief executive officer of AnaptysBio ,